Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis
- PMID: 11050265
- PMCID: PMC1745639
- DOI: 10.1136/thorax.55.11.946
Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis
Abstract
Background: Health related quality of life (HRQoL) measurement is important in determining the impact of disease on daily functioning and subsequently informing interventions. In cystic fibrosis (CF) generic HRQoL measures have been employed but these may not be sufficiently specific. The aim of the current work was to develop and validate a disease specific HRQoL measure for adults and adolescents with cystic fibrosis.
Methods: Areas of concern to adults and adolescents with CF were identified by unstructured interviews, self-administered questionnaires, consultation with multidisciplinary specialist staff, a review of the relevant literature, and examination of other HRQoL measures. Items for the questionnaire were generated on the basis of this process. Continued evaluation and development of the Cystic Fibrosis Quality of Life (CFQoL) questionnaire was undertaken by a process of statistical analysis and continued feedback from patients. The full testing and validation of the CFQoL questionnaire took place over four phases: (1) initial item generation and testing of a preliminary questionnaire, (2) testing and validation of the second version of the questionnaire, (3) test-retest reliability of a third and final version of the questionnaire, and (4) sensitivity testing of the final version of the questionnaire.
Results: Nine domains of functioning were identified using principal components analysis with varimax rotation. Internal reliability of the identified domains was demonstrated using Cronbach alpha coefficients (range 0.72-0.92) and item to total domain score correlations. Concurrent validity (range r = 0.64-0.74), discriminatory ability between different levels of disease severity, sensitivity across transient changes in health (effect size range, moderate d = 0.56 to large d = 1.95), and test-retest reliability (r = 0.74-0.96) were also found to be robust.
Conclusions: The CFQoL questionnaire is a fully validated disease specific measure consisting of 52 items across nine domains of functioning which have been identified by, and are of importance to, adolescents and adults with cystic fibrosis. This measure will be useful in clinical trials and longitudinal studies.
Similar articles
-
Validation of the Italian version of the Cystic Fibrosis Quality of Life Questionnaire (CFQoL), a disease specific measure for adults and adolescents with cystic fibrosis.J Cyst Fibros. 2008 Mar;7(2):116-22. doi: 10.1016/j.jcf.2007.06.003. Epub 2007 Aug 24. J Cyst Fibros. 2008. PMID: 17719279
-
Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis.Chest. 2005 Oct;128(4):2347-54. doi: 10.1378/chest.128.4.2347. Chest. 2005. PMID: 16236893
-
[Validation of Polish version of CFQoL in patients with cystic fibrosis].Pol Merkur Lekarski. 2007 Nov;23(137):340-3. Pol Merkur Lekarski. 2007. PMID: 18361315 Polish.
-
[CFQoL questionnaire as an assessment tool of quality of life in patients with cystic fibrosis].Pol Merkur Lekarski. 2007 Aug;23(134):137-40. Pol Merkur Lekarski. 2007. PMID: 18044346 Review. Polish.
-
Quality of life and exercise tolerance tools in children/adolescents with cystic fibrosis: Systematic review.Med Clin (Barc). 2022 Jun 10;158(11):519-530. doi: 10.1016/j.medcli.2021.06.025. Epub 2021 Sep 8. Med Clin (Barc). 2022. PMID: 34507821 English, Spanish.
Cited by
-
Vitamin K supplementation for cystic fibrosis.Cochrane Database Syst Rev. 2020 Jun 4;6(6):CD008482. doi: 10.1002/14651858.CD008482.pub6. Cochrane Database Syst Rev. 2020. PMID: 32497260 Free PMC article.
-
Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis.Cochrane Database Syst Rev. 2019 Apr 18;4(4):CD009876. doi: 10.1002/14651858.CD009876.pub4. Cochrane Database Syst Rev. 2019. PMID: 30997925 Free PMC article.
-
Recombinant growth hormone therapy for cystic fibrosis in children and young adults.Cochrane Database Syst Rev. 2021 Aug 23;8(8):CD008901. doi: 10.1002/14651858.CD008901.pub5. Cochrane Database Syst Rev. 2021. PMID: 34424546 Free PMC article.
-
Vitamin K supplementation for cystic fibrosis.Cochrane Database Syst Rev. 2017 Aug 22;8(8):CD008482. doi: 10.1002/14651858.CD008482.pub5. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jun 4;6:CD008482. doi: 10.1002/14651858.CD008482.pub6. PMID: 28829533 Free PMC article. Updated.
-
A cardiac-specific health-related quality of life module for young adults with congenital heart disease: development and validation.Qual Life Res. 2004 May;13(4):735-45. doi: 10.1023/B:QURE.0000021690.84029.a3. Qual Life Res. 2004. PMID: 15129884
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical